(439) Loteprednol etabonate-loaded nanoemulsion: anti-inflammatory effect

Loteprednol etabonate (LE) is approved in the form of a suspension for the short-term treatment of the signs and symptoms of dry eye disease (DED) (1). An oil-in-water nanoemulsion is a potentially better choice for DED treatment because it not only efficiently delivers a drug with limited aqueous solubility to the inflamed ocular epithelia but also stabilizes the compromised tear film (2,3). We have developed LE-loaded NE with finely tuned physicochemical and biopharmaceutical properties. In this study, the anti-inflammatory effect of LE-loaded NE was investigated using an in vitro DED model.